PAHSCO Business Summary

Pacific Hospital Supply Co., Ltd. (PAHSCO) operates a vertically integrated business model specializing in the design, manufacture, and global distribution of disposable medical devices and hospital infrastructure systems. Revenue is primarily generated through the sale of high-volume medical consumables across four core segments: Closed Wound Drainage Systems, Respiratory Therapy and Anesthesia products, Surgical Suction instruments, and Centralized Medical Gas Piping Systems. The company maintains a robust OEM/ODM division alongside its proprietary PAHSCO brand, exporting to over 80 countries while serving as a dominant supplier for Taiwan’s domestic healthcare infrastructure. In the competitive landscape, PAHSCO contends with global medical technology firms such as Teleflex and B. Braun in specialized drainage and suction niches, as well as large-scale regional manufacturers like Zhende Medical and Winner Medical. PAHSCO distinguishes itself through its dual-competency in both sterile consumables and complex engineering for medical gas systems, positioning it as a specialized mid-cap player with higher technical barriers than commodity-focused medical supply peers. The leadership team is headed by Chairperson and CEO An-Ting Chung, who has been instrumental in steering the company’s international expansion and securing critical quality certifications, including ISO 13485 and MDR. The executive management is further supported by General Manager Tim Chiang, who oversees global operations and administrative strategy. A significant strategic pillar of PAHSCO’s corporate structure is the involvement of Catcher Technology Co., Ltd., which remains a major institutional shareholder and maintains board representation through Director Stanley Chen. The board is characterized by a blend of long-term stewardship and professional oversight, featuring independent directors like Vance Chin and Adrian Chang, who provide expertise in healthcare management and financial governance. The company’s stable capital base is further bolstered by international institutional investors, including Dimensional Fund Advisors and State Street Global Advisors, reflecting its status as a reliable dividend-paying entity within the TPEx healthcare sector.